Advancing Treatment of Chronic Kidney Disease in Patients With Diabetes: Key Considerations for Pharmacists

Advancing Treatment of Chronic Kidney Disease in Patients With Diabetes: Key Considerations for Pharmacists

On-Demand Accredited Online Article

Faculty

Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP
Vice-Chair & Associate Professor
Department of Pharmacotherapy
College of Pharmacy and Pharmaceutical Sciences
Washington State University
Spokane, Washington
 
Program Description
Patients with diabetes commonly have comorbid conditions affecting the cardiovascular system and the kidneys. Research indicates that damage to small blood vessels occurring due to diabetes and high blood pressure may be predictors for development of chronic kidney disease (CKD). While medication therapy has led to declines in cardiovascular disease-related mortality, incidence of CKD progressing to end-stage renal disease (ESRD) continues to be a high-risk complication for persons with diabetes. Goals of treatment have been to minimize complications through lifestyle interventions and management of hyperglycemia and hypertension. Pharmacists on the supportive care team have important roles in filling communication gaps between providers, identifying patients with diabetes with comorbid conditions who may be at risk for developing CKD, and helping to manage medication regimens. Investigations into currently available steroidal mineralocorticoid receptor antagonists (MRAs) have demonstrated reduction in cardiovascular mortality and are currently under investigation for use in patients with type 2 diabetes and CKD. This activity will delve into emerging clinical data for MRAs and present interventions pharmacists can make to help improve outcomes of patients with type 2 diabetes and CKD.

Target audience: Retail pharmacists
Type of activity: Application
Release date: July 30, 2021
Expiration date: August 31, 2022
Time to complete activity: 2.0 hours
Fee: Free

Educational Objectives
At the completion of this activity, participants will be able to:

• Identify the epidemiology of diabetes and chronic kidney disease (CKD) as well as the pathology of kidney disease in this patient population and the impact of inflammation and fibrosis as a progressive factor
• Analyze current guidelines for CKD and type 2 diabetes (T2D) and the clinical trial data surrounding the emerging nonsteroidal mineralocorticoid receptor antagonists in treatment
• Illustrate the impact of pharmacists in coordination of care and treatment strategies for CKD in patients with T2D

 Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.20 CEU) under the ACPE universal activity number 0290-0000-21-284-H01-P. The activity is available for CE credit through August 31, 2022.


Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, read the article in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP, has the following relevant financial relationships with commercial interests to disclose:

• Consultant: Novo Nordisk
• Speakers Bureau: Dexcom

Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Michelle C. Carlson, PharmD; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers are used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms